Tirapazamine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
|
WikiDoc Resources for Tirapazamine | |
|
Articles | |
|---|---|
|
Most recent articles on Tirapazamine Most cited articles on Tirapazamine | |
|
Media | |
|
Powerpoint slides on Tirapazamine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Tirapazamine at Clinical Trials.gov Clinical Trials on Tirapazamine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Tirapazamine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Tirapazamine Discussion groups on Tirapazamine Patient Handouts on Tirapazamine Directions to Hospitals Treating Tirapazamine Risk calculators and risk factors for Tirapazamine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Tirapazamine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.
Chemically it is an aromatic heterocycle di-N-oxide. Its full chemical name is 3-amino-1,2,4-benzotriazine-1,4 dioxide. Originally it was prepared in a programme screening for new herbicides in 1972. Its clinical use was first described by Zeman et al in 1986.
References
- Denny WA (2004). "Prospects for hypoxia-activated anticancer drugs". Curr Med Chem Anti-Canc Agents 4 (5): 395-9. PMID 15379691.
- Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH (2002). "Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia". Semin Oncol 29 (1 Suppl 4): 102-9. PMID 11894020.
- Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986). "SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells". Int J Radiat Oncol Biol Phys 12 (7): 1239-42. PMID 3744945.
External link
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
